At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
In Brief
A Phase 1 clinical trial evaluating Biospecimen Collection, Magnetic Resonance Imaging, and 2 other interventions for Recurrent Diffuse Intrinsic Pontine Glioma and 7 related conditions. Active but no longer recruiting, targeting 41 participants across 12 sites in 2 countries.
Signals
Detailed Summary
This phase I trial studies the side effects and best dose of savolitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Timeline
Arms & Interventions
Patients receive savolitinib PO QD. Treatment repeats every 28 days for up to 39 courses in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, X-ray imaging, and MRI scans throughout study.
Interventions
Undergo blood sample collection
Undergo MRI scan
Given PO
Undergo X-ray imaging